Macrophage Activation Syndrome (MAS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
_page-0001.jpg)
Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases in childhood, mainly systemic Juvenile Idiopathic Arthritis (sJIA). MAS is typically characterized by high fever, lymphadenopathy, hepatosplenomegaly, hemorrhages, and signs of liver, central nervous system, and kidney involvement, potentially leading to multiple organ failure. Laboratory abnormalities in MAS include leukopenia, thrombocytopenia, anemia, hypertransaminasemia, markedly elevated ferritin levels, and evidence of intravascular coagulation activation. MAS is generally classified among the secondary forms of hemophagocytic lymphohistiocytosis (sHLH), as it occurs in the context of rheumatic disease. MAS and HLH share numerous clinical and laboratory features, with notable differences attributable to the inflammatory background of MAS, such as higher platelet counts and fibrinogen levels compared to primary HLH (pHLH). Primary HLH is caused by mutations in genes encoding proteins involved in perforin-mediated cytolytic function, including perforin and proteins associated with vesicle transport and membrane fusion. Secondary or acquired HLH, which appears more frequent than pHLH, can be triggered by various conditions. Among infection-associated HLH, Epstein-Barr Virus is the most common trigger, with other typical triggers including Herpes viruses, Leishmania, and H1N1 influenza. HLH can also be associated with lymphoma and leukemia, particularly T-cell receptor gamma-delta bearing T-cell lymphomas, which are more common in adults than in children. Additionally, HLH can arise in the context of an underlying rheumatic disease, with sJIA being the most frequent association, referred to as MAS or rheuma-HLH by pediatric rheumatologists. In some cases, no apparent underlying disease or infection is identifiable. Early treatment should include corticosteroids, often in conjunction with intravenous gamma globulin. This approach usually leads to rapid symptom resolution. Steroid doses should be tapered gradually to prevent relapse. If initial treatment fails to significantly improve the patient's condition, then treatment with HLH-directed regimens should be initiated.
Thelansis’s “Macrophage Activation Syndrome (MAS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macrophage Activation Syndrome (MAS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Macrophage Activation Syndrome (MAS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Macrophage Activation Syndrome (MAS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment